DENVER, Jan. 25, 2006 - Fischer Imaging Corporation (FIMG.PK) entered into an arrangement on January 23, 2006 for Kodak to offer service and support to the worldwide installed base of Fischers mammography products, including SenoScan digital mammography and MammoTest stereotactic breast biopsy systems. Fischer had consummated the sale of its mammography assets (all intellectual property rights used in Fischers mammography business, including the SenoScan and MammoTest systems) to Hologic, Inc. on September 29, 2005. Fischer, with Hologics consent, granted Kodak a nonexclusive limited license to use certain mammography assets necessary to provide service and support on the installed base of SenoScan and MammoTest systems.

Under the agreement, it is expected that Kodaks Health Group will provide postsale support, including telephone customer technical support and onsite equipment repair and maintenance, to Fischers service customers who enter into a Kodak service agreement. We believe this arrangement will provide our mammography customers with access to repair and maintenance support from a large, reputable and highly responsive organization, said Dr. Gail Schoettler, chairperson of the board.

As a result of this arrangement, Fischer will notify all of its mammography service customers and suppliers of Kodaks role as an authorized service provider. Kodak will contact mammography service customers and offer them the opportunity to enter into a service agreement directly with Kodak. Fischer will offer those customers who desire to enter into a service agreement with Kodak, the ability to terminate their current service contracts with Fischer without penalty. In addition, Fischer expects to enter into service agreements with Kodak to arrange for Fischers customers with equipment still under
manufacturers warranty to receive service and support from Kodak at no additional cost to those customers. Kodak will also have the right to have spare parts and consumables manufactured for its use, sale and distribution.

Fischer intends to continue its service business until April 21, 2006, as well as fulfill its contractual obligations to provide MammoTest to Ethicon EndoSurgery while it explores strategic alternatives for its radiology, electrophysiology, and surgical (RE&S) business. As discussed more fully in the Form 10Q for the quarter ended September 30, 2005, management cannot accurately estimate the amount of distribution to its stockholders, if any, from the proceeds of the Hologic Sale until the following are finalized or resolved:

More Voices